Whats more, because GLP-1s are not banned, theres no need to name the others specifically while the advisory group collects data on how the market leader is being used, Rabin says
Physiol Rev (2007) 87:140939
A patient who lost weight but developed fatigue, constipation, under-eating, or muscle weakness may need a different strategy than a patient who lost weight steadily, maintained strength, and improved lab markers
8,14,15 Although most approved GLP-1RAs and co-agonists have not yielded satisfactory results in histological endpoint clinical trials, the future of managing and treating MASLD holds promise
Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction